TRVI
Trevi Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.71 / 10
Netural
With a fund flow rating of 7.94/10, the stock shows robust fund flow characteristics. Supportive momentum from overall, block, Small, Medium, and Extra-large trends is partially offset by concerning Large patterns, pointing to positive capital flow trajectory. Analyst coverage indicates overwhelmingly bullish analyst consensus with strong conviction. Rating distribution: Strong Buy(100.0%) among 2 analysts, supported by 3.47 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for TRVI?
- TRVI holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.71/10 (Netural).
